Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Aptar Pharma advances digital offerings

Partners up with digital therapeutics company Propeller Health

AptarFurther strengthening pharma’s stance in the digital health field, prescription drug and consumer healthcare group Aptar Pharma has teamed up with Propeller Health in a bid to develop digital medicines in multiple therapeutic areas.

The “comprehensive” platform, which will span inhaled, injectable, nasal and dermal medicine delivery forms, will combine software with connected drug delivery devices.

Aptar Pharma will work with its new partner together with pharmaceutical and healthcare associates to accelerate the development, manufacturing and commercialisation of digital medicines for marketed and pipeline brands.

Propeller and Aptar Pharma will co-market the platform, with the former managing digital services and the latter handling device development, manufacturing and supply chain.

David Van Sickle, co-founder and CEO of Propeller, said: “Propeller draws on nearly a decade of experience pioneering digital respiratory medicines and putting them to work in healthcare organizations around the world.

“Our end-to-end infrastructure enables fast, flexible and secure development and commercialisation of digital medicines.”

Digital therapeutics, dubbed ‘digiceuticals’, has been somewhat of a focus for the industry as of late, with studies showing that this particular therapeutic advancement can help personalise treatments, monitor patients in real-time, detect day-to-day changes in disease conditions and increase patient adherence.

Salim Haffar, president of Aptar Pharma, commented: we are excited to broaden our offerings as we continue this journey towards improved patient care and clinical outcomes by growing our partnership with Propeller Health the leader in their field of digital therapeutics

The two companies initially partnered in 2016 to develop, what the companies say, is the world’s first fully-integrated connected metered dose inhaler (cMDI).

In addition to the expanded partnership, Aptar Pharma has made a strategic equity investment of $10m in Propeller Health during their latest funding round.

Article by
Gemma Jones

7th June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics